Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

Phase 1/2 Terminated 78 enrolled TG Therapeutics, Inc. James P. Wilmot Cancer Center · collab

Non-randomizedSingle-groupOpen-labelTreatment

Phase I/II Study of Venetoclax or Lenalidomide in Combination with Ublituximab and Umbralisib in Subjects with Relapsed or Refractory CLL/SLL and NHL

Outcome not reported

Stopped (Business): “Strategic/Business Decision”

Evaluation	Drug	Modality	Dose	Route
Subject	Lenalidomide	Other / unclassified	—	—
Subject	Venetoclax	Small molecule	—	Oral
Background	Ublituximab	Monoclonal antibody	—	Intravenous
Background	Umbralisib	Small molecule	—	Oral